{"nctId":"NCT00256698","briefTitle":"Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy","startDateStruct":{"date":"2004-01"},"conditions":["Breast Cancer"],"count":514,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anastrozole"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Fulvestrant","Drug: Anastrozole"]}],"interventions":[{"name":"Fulvestrant","otherNames":["Faslodex","ZD9238"]},{"name":"Anastrozole","otherNames":["Arimidex","ZD1033"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent, postmenopausal females, histological or cytological confirmed oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence or metastasis\n\nExclusion Criteria:\n\n* Previous systemic endocrine therapy for advanced or recurrent disease; prior fulvestrant therapy\n* Premenopausal women","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Progression (TTP)","description":"RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve \"respond\", stay the same \"stable\"or worsen \"progression\" during treatments.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Evaluable Participants With Objective Response Rate (ORR)","description":"No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Clinical Benefit Rate (CBR) Responders","description":"No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"55.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Clinical Benefit (DoCB)","description":"Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"18.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure (TTF)","description":"Time from randomisation until the date of discontinuation of randomised treatment for any reason","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival is equivalent to time to death. Time from randomisation until the date of death","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"38.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":256},"commonTop":["Fatigue","Arthralgia","Nausea","Hot flush","Diarrhoea"]}}}